Arcas News
The article “The Big Reset” reviews the first decade of the millennium, and discusses trends and forecasts for 2010. It has been published in the January edition of Pharmaceutical Executive. Arcas President Jan Heybroek is quoted in the piece on pharma licensing trends as: “Yet the jump in the number of givebacks in 2009 may signal a resurgeance in acquisitions in 2010. You have to very actively manage licensing relationships, and there’s plenty of evidence that the divorce rate is as high as it is for people.” You can read a full copy of the article here: The Big Reset - PharmExec Jan 2010.
For more information on Arcas and MDoutlook, our unique and innovative oncology intelligence resource, please contact us at 1.866.30utlook | +1.404.496.4136 | email.
February 17th, 2010
Earlier this month, MDoutlook® - our unique and innovative oncology intelligence resource - reached another milestone: profiles of more than 45,000 oncology treaters worldwide now are available.
MDoutlook provides unprecedented insight into several key areas of the oncology landscape in a disease-targeted manner. These areas include:
- ThoughtLeader, practicing clinician, and institutional profiling combining physician-self and Arcas-team validated and updated information with real-time data feeds from reputable external sources;
- Real-time treatment logs of patients per oncology disease target;
- Individual and aggregate physician treatment profiling, inclusive of patient flow and volume;
- And, through the MyActivities Module of MDoutlook, an unmatched resource and platform for the daily collection, analysis and reporting of sales and marketing interactions, company activities and market intelligence, at the individual ThoughtLeader and practicing clinician levels.
MDoutlook uncovers not only the therapeutic choices oncologists make (quantitative), and the considerations, rationale, and ThoughtLeaders influencing their decisions (qualitative), in one easily accessible, focused resource. This insight is captured through targeted surveys to physicians treating the target disease, dedicated treater panels/treatment logs, and corresponding analyses and reports. And importantly, this insight is guided and interpreted through direct and exclusive consultation with top peer-identified ThoughtLeaders in each of the target disease areas.
The MDoutlook Intelligence Platform features in-depth and easily accessed information for your entire organization; real-time updating of streaming data; on-demand information sorting, prioritization analysis, and reporting; interactive links between networks of clinicians, ThoughtLeaders, and Institutions; and sophisticated information searching.
Interested? Please contact us at +1.866.3outlook | 1.404.496.4136 | email for more information and to schedule a demo.
February 17th, 2010
We are proud to announce our support and affiliation with the 2nd Oncology USA Summit, to be held Mar 23-24 in Boston, MA. This exciting, first-tier event will offer our clients and other marketing executives new perspectives on oncology commercialization, and relevant case studies. As a client of Arcas, we are able to offer you an exclusive $300 discount on your conference registration - for more details and registration see below.
How do you engage all stakeholders in a challenging oncology market place? With 6 VP speaker insights and the top oncology companies represented, we will demonstrate how to articulate your value proposition to a wider audience.
This is your chance to be part of an interactive forum to ultimately take away knowledge that enables you to take your oncology commercialization strategy to the next level. This information-driven gathering will bring together senior level executives in the industry to network, as well as refreshing and refocusing your knowledge.
Event title: 2nd Annual Oncology USA
Dates: March 23-24 2010
Location: Boston Park Plaza, Boston, USA
Contact details: Claire Poole - cpoole@eyeforpharma.com
www.eyeforpharma.com/oncologyusa
To benefit from a special discount of $300 as valued Arcas client, please click on this registration link and quote ‘Arcas‘.
Looking forward to seeing you in Boston!
January 6th, 2010
In working so closely with our clients and over-delivering on our promises, client focus and project delivery is constantly and squarely front-of-brain. Our projects tend to be long(er) commitments in which our relationships develop as we look for more and better ways to support our clients’ success. It is a matter of great professional pride when we receive - unsolicited - accolades for our work.
Here is a recent selection:
- “I just want to thank you for the time we have been working together. I think it has been a great experience. Seldom do I come across a team so professional as you are; intelligent, knowledgeable, produce good things and on time. Very impressive.”
Executive, New Media Company - Boston, MA
- “You are true oncology experts. I trust your guidance and recommendations implicitly. I have been in oncology marketing for almost two decades and your network of thoughtleaders is unsurpassed.”
Director, Oncology Marketing - San Diego, CA
- “MDoutlook is delivering exactly the oncology intelligence I was looking for. I’m slightly overwhelmed by the amount of information you have been able to uncover, analyze and deliver in less than 30 days.”
Director, Marketing - Princeton, NJ
- “Your team is awesome. The quality of the deliverables and the ease of collaboration is much better what the two previous companies were able to provide me. I love it!”
Renowned Breast Cancer Expert - Miami, FL
Contact us at info@thearcasgroup.com, +1.404.496.4136 for more information, client references and to discuss how we can support your commercial growth.
December 7th, 2009
The Arcas Group is pleased to announce the recent article discussions of two studies conducted by the MDoutlook intelligence system. The first study, conducted in partnership with Oncology Business Review, focused on uncovering new ideas, gauging support for current proposals, and collecting opinions about how reimbursement and drug access changes may affect the cost and quality of cancer care in the US. The sheer number of comments to this survey (more than half of the sample) suggests oncologists are eager to have a voice in healthcare reform. Full results are available via this OBR article on MDoutlook.
The second study, featured in Med Ad News, highlighted the results of MDoutlook Quick Polls performed following ASCO 2009. The Arcas Group, in close consultation with members of the MDoutlook Strategy Council, selected key oncology developments presented at the ASCO Annual Meeting in Orlando. Within one week, 370 cancer treaters from 32 countries completed these Quick Polls making it the first market feedback available. Members of the MDoutlook Strategy Council believe these results validate the expected change in physician decision-making. Story and results of the Quick Poll are available via Med Ad News article on MDoutlook.
MDoutlook (www.thearcasgroup.com/mdoutlook) is an innovative proprietary, web-based intelligence resource. By offering unprecedented connectivity to 43,000 cancer treaters worldwide, MDoutlook delivers a better, more comprehensive view of the oncology marketplace for its BioPharma subscribers. To find out how MDoutlook can provide actionable insight for your commercialization strategy, please contact us at info@mdoutlook.com or call +1.404.496.4136.
October 12th, 2009
We are very pleased to announce that Michael Johnson has recently strengthened the Arcas leadership team. He brings to our clients and our team an impressive experience in oncology marketing and commercialization, from both the life sciences industry as well as the service provider side.
Michael’s expertise spans the full range of commercialization strategy and implementation, including pharmaceutical sales, sales training, marketing communications, strategic brand management, ThoughtLeader identification and management, live and online CME meeting development and direction, commercial market research and intelligence.
“I am thrilled to welcome Michael to our team. In previous organizations, I have had the distinct pleasure of working with Michael and have been duly impressed by his deep understanding of the (oncology) market place, navigating its challenges and maximally exploring the many opportunities. Michael is a great addition to the team and resource to our clients,” says Jan Heybroek, President of The Arcas Group, LLC. Click here for Michael’s bio.
Michael can be reached directly at mjohnson@thearcasgroup.com and +1.484.365.2334.
October 12th, 2009
Walter Armstrong of Pharmaceutical Executive has written an excellent perspective on the CEO of Sanofi-Aventis, Chris Viehbacher, six months into his new position. You can review the article online at or download a PDF copy here.
Arcas’ President Jan Heybroek was quoted several times in the article:
- “The pharma business is now more than ever about sales—and about solid assumptions and actual delivery—as opposed to interesting science that may or may not work,” said The Arcas Group’s Jan Heybroek.
- “Oncology is a very lucrative field requiring very specialized skill sets. Given Sanofi’s past success in major tumor types, the company should have already gained traction in the smaller tumor types,” says The Arcas Group’s Heybroek. “But its pipeline is nowhere near as deep and diverse as, say, Novartis’.”
- In his brief tenure, he has already clocked many thousands of miles in air travel and spent billions in biotech ollars, and found time to pay “only the odd visit to my wife and three children.” Where does Viehbacher’s rive come from? Is it the money? His early childhood? The dynamism Viehbacher has introduced is undeniable. “He’s the real deal,” says Heybroek. “He’s confident enough to allow communication and ontention to emerge and not to need to hide behind an entourage. He can inspire people to follow him.”
For more insight into the oncology market, don’t hesitate to contact us by phone (+1.404.496.4136) or email.
August 13th, 2009
The Arcas Group is pleased to present results from its MDoutlook Quick Poll among 3,600+ GI cancer treaters in 28 countries. This survey was fielded to assess the impact on clinical practice based on data presented at the 2009 World GI Cancer Congress and ASCO. The report is available via this: LINK Please feel free share your thoughts/comments. We will gladly provide the report in PowerPoint format upon request.
July 28th, 2009
Atlanta, GA — MDOUTLOOK®, the innovative oncology intelligence platform, today announced the results from its Quick Poll research, which was launched immediately following this month’s annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. Based on patient volume, clinical focus and other criteria, specific subgroups of MDOUTLOOK’s global database of 43,000 cancer treaters were selected for participation in one of the following Quick Polls: integration of hot topics in the management of breast cancer, gynecological cancer, lung cancer or skin cancer (melanoma).
MDOUTLOOK, in close consultation with members of the MDOUTLOOK Strategy Council and other renowned medical experts, selected key oncology developments presented in Orlando for each of the four researched areas. Within one week, 370 cancer treaters from 32 countries completed these Quick Polls making it the first market feedback available post-ASCO. The research yielded the following highlights:
Breast Cancer:
• High level of excitement surrounds the development of PARP1 inhibitors BSI-201 and olaparib for the treatment of triple-negative breast cancer.
• Development of PARP1 inhibitors is expected to double the amount of genetic screening for Breast Cancer Susceptibility Gene (BRCA) deficiencies.
Gynecological Cancers:
• Combination of carboplatin + pegylated liposomal doxorubicin will be the new standard-of-care for relapsed, platinum-sensitive ovarian cancer
• For advanced cervical cancer, the combination of gemcitabine + cisplatin will be the new standard-of-care concerning choice of chemotherapy.
Maintenance therapy in Non-Small Cell Lung Cancer:
• Only a minority of applicable patients currently receive this therapy in their treatment
• Substantial amount of enthusiasm surrounds the new information on the use of maintenance therapy for advanced NSCLC presented at ASCO. This will result in an estimated 40% increase in use of maintenance therapy
• Pemetrexed appears the top choice.
Advanced stage Melanoma:
• Ulceration status of the primary lesion will become key differential factor driving the use of PEG-IFN-α-2b. This is a change from current practice
• High level of excitement around the BRAF inhibitor PLX4032, leading to strong interest in clinical trial participation
• Malignant melanoma is entering the “age of targeted therapies” through the use of screening for BRAF and KIT mutations, driving the selection of appropriate therapies.
Members of the MDOUTLOOK Strategy Council reflected that these results “validate the expected change in physician decision-making” and that “it will be interesting to follow-up on a regular basis to track these changes”. Jan Heybroek, President of The Arcas Group, LLC, which powers MDOUTLOOK commented: “These Quick Polls perfectly demonstrate the ability of MDOUTLOOK to quickly and in a targeted manner capture the view of the clinician, and turn this into actionable intelligence.”
Full copies of the MDOUTLOOK Quick Poll results can be requested.
MEDIA CONTACTS:
Jan A. Heybroek, MSc, MBA
+1.404.496.4136
jan@thearcasgroup.com
About MDOUTLOOK®
MDOUTLOOK has been developed with a singular focus: improved understanding of complex disease areas leading to better patient care. The program is guided by globally recognized experts, such as Chandra Belani, MD; Alexander Eggermont, MD; Keith Flaherty, MD; Axel Hauschild, MD; Peter Heald, MD; John Kirkwood, MD; Lauren Pinter-Brown, MD; Giorgio Scagliotti, MD, PhD; Orlando Silva, MD, JD; and Nicholas Thatcher, MD.
MDOUTLOOK delivers clients real-time treatment decisions and rationale, treater and institution profiles, and ThoughtLeader analysis via the web (www.thearcasgroup.com/mdoutlook).
MDOUTLOOK delivers value per this comment from a Group Marketing Director Oncology: “Our analysis showed that MDOUTLOOK was by far the most comprehensive, up-to-date and cost-effective intelligence program available. Its accessibility across many functions in our organization greatly supports our internal knowledge and market understanding.”
MDOUTLOOK directly collaborates with more than 43,000 cancer treaters globally and covers all major and smaller oncology areas, including lung cancer, breast cancer, gastrointestinal cancer, genitourinary cancer, gynecological cancer, hematological malignancies, and melanoma. MDOUTLOOK is being launched in other complex diseases, such as Rheumatoid Arthritis, Ophthalmology, Parkinson’s Disease, and Alzheimer’s.
About The Arcas Group
The Arcas Group (www.thearcasgroup.com) supports the commercial success of clients in the continuum of life sciences marketing – from marketing intelligence to strategy development and implementation – through enhanced connectivity with ThoughtLeaders and Clinicians.
Arcas serves its clients through three offerings:
• MDOUTLOOK | Disease Intelligence and ThoughtLeader Insight;
• Business Optimizer™ | Growth Consultancy
• Outcome Optimizer™ | Medical Strategy Implementation.
Leadership combines more than 80 years of experience in domestic and global life sciences. Our team has worked with over 100 different life science organizations throughout their career, spanning a wide range of therapy and functional areas.
June 24th, 2009
We invite life sciences executives with an oncology focus to join the MDoutlook Strategy Council to discuss cancer treatment from a clinician’s point of view. Meetings will be scheduled on May 28 at Peabody Hotel Orlando in conjunction with ASCO 2009. We will accommodate your schedule for convenient meeting times.
For complete details and RSVP, please contact Craig Krugman, Vice President, Client Services & Strategy at +1.404.452.5988, ckrugman@thearcasgroup.com. View your invitation here.
MDoutlook is an exclusive web-based platform that provides a clinician’s view of the United States and European oncology landscape to drive your commercial success.
MDOUTLOOK delivers:
· Real-time insight into clinical treatment behavior – with a singular focus on treatment decisions and rationale
· Exclusive access to unique ThoughtLeader driven analysis, intelligence and perspective
· Comprehensive profiles of cancer treaters, ThoughtLeaders, investigators and institutions; incl. ThoughtLeader mapping.
The MDoutlook Strategy Council will be on hand to privately discuss the landscape of cancer treatment, and to demonstrate how MDoutlook delivers critical marketing intelligence and insight that will directly contribute to your commercial success. Download a synopsis of MDoutlook here.
We look forward to seeing you at ASCO!
May 7th, 2009
Previous Posts
